The clinical utility of molecular diagnostic approaches in allergy investigation is being recognized increasingly to play a significant role in the management of allergic patients. Determining the sensitization pattern, which is best achieved through the use of component resolved diagnostics (CRD), allows effective risk stratification, appropriate treatment and patient selection for immunotherapy. In order to assess the diagnostic service provisions for in-vitro allergy testing across Europe, a survey was carried out via the total immunoglobulin (Ig)E and specific IgE external quality assurance schemes run by UK National External Quality Assessment Service (NEQAS) Immunology, Immunochemistry and Allergy. This survey assessed allergy testing, and in particular allergen components offered by the laboratories, and found a wide variability in service provision, particularly between the United Kingdom and other European Union (EU) countries. Furthermore, there was lack of standardization for acquisition of clinical information to aid allergen (and component) selection, gating strategy, testing algorithms and clinical interpretation. Interestingly, a significant proportion of laboratories (the majority from EU) stated that they 'used' the results for peanut components for risk stratification. However, the vast majority of participants were unaware of guidelines relating to the use of allergen component testing, and agreed that further education would assist in reaching a common platform. Hence, this survey has highlighted that although CRD has been adopted into routine diagnostics across Europe, it is potentially compromised by lack of standardized protocols and guidance sources. Consequently, there is a need for local or national standards and education through External Quality Assurance services on the performance and application of CRD into allergy investigation.
Introduction
Recent developments in molecular techniques have given rise to advances in the knowledge of properties of specific allergens, and have aided their clinical utility in both diagnosis and management of allergic patients. These advances have allowed for the use of specific allergen components in in-vitro diagnosis in what is termed molecular diagnosis, or component-resolved diagnosis (CRD) [i.e. identifying specific immunoglobulin (Ig)E to distinct allergenic subcomponents of the whole allergen extract]. CRD provides clinicians with an extended diagnostic toolkit with potential for cross-sensitization profiling, risk stratification and allergen identification for improved patient management [1, 2] . Benefits to the patient may include negating the need to undergo the risk of an oral food challenge where sensitization to high-risk components is present, or eliminating the requirement for dietary exclusions where cross-reactive components associated with low risk of systemic reactions are identified [3] . These potential patient benefits are important when considering patient health, quality of life and the risks and costs associated with challenge tests. Worldwide data suggest that the prevalence of allergy is increasing. A recent systematic review of food allergy across Europe assessed prevalence of food allergy in both adults and children [4] . A pooled lifetime prevalence of selfreported allergy was found to be 17Á3%, with point prevalence of 5Á9%. Sensitization to more than one food, as indicated by specific IgE, was found in 10Á1%. However, the prevalence of true allergy, as confirmed by food challenge (either open or double-blind placebo-controlled), was much lower, at 0Á89% in children and 0Á99% in adults (overall point prevalence of 0Á93%). This distinct discrepancy between self-reporting in-vitro sensitization assessment and confirmed food allergy illustrates the need for a greater use of more accurate diagnostic testing to diagnose or exclude allergy. The difference in prevalence between self-reported allergy and clinically confirmed allergy was reflected across Europe [4, 5] , with the greatest difference seen in northern Europe (14Á51% self-reported; 1Á12% confirmed point prevalence). Unfortunately, clinical falsepositivity, the prevalence of detectable but irrelevant sensitization to whole allergen extracts which does not lead to clinical symptoms, is often much higher than true clinical allergy for many allergens.
When assessing and reporting allergy, the distinction between asymptomatic sensitization (often caused by invitro cross-reactivity) and clinical symptomatic allergy is vital. CRD has demonstrated its clinical utility within allergy management by providing the user with the ability to make a differential diagnosis between primary allergen sensitization and cross-reactive allergens (that share structural similarity) such as birch PR-10 homologues. Panels of CRD allergens have been shown to be of clinical value in prevalence studies, and sensitization patterns can sometimes indicate the probable severity of symptoms to fruit and plant food allergens [3, 6, 7] .
The European prevalence of peanut sensitization may be as high as 2Á7% [6] , but only one in five of these may have clinically significant allergic symptoms. In a study of childhood peanut allergy, 22Á4% of sensitized 8-year-olds (of 933 participants) had confirmed peanut allergy by doubleblind placebo-controlled food challenge [8] . Comparison of sensitization rates to individual components determined the peanut component Ara h 2 to be the best predictor of clinical outcome. The clinical utility of Ara h 2 was also shown by a prospective study comparing specific IgE to peanut Ara h 2 and outcome of food challenge [7] . Ara h 2 and Cor a 14 were better discriminators of allergy from tolerance than whole peanut or hazelnut extracts, respectively. In a separate study, Ara h 2 sIgE had the best correlation with challenge outcome, superior to Ara h 1, 3, 8, 9 and peanut-specific IgE [9] . The close association of an immunodominant major component sensitization (often referred to a species-specific sensitization) to probability of clinical allergy is to be expected; however, the presence of crossreactive sensitization obscures the presence or absence of species-specific sensitization. Thus, identifying or eliminating signals from cross-reactive components is a key feature in component assay performance. Ara h 1, 2, 3 and 6 are species-specific allergen components associated with clinical peanut allergy, but Ara h2 is associated most strongly and is the best predictor in isolation. Conversely, sensitization to the cross-reactive PR10 protein such as Ara h 8 alone is often a marker of false positivity due to pollen sensitization and associated predominantly with minor reactions [10] .
The use of component testing is increasing as clinicians seek to improve allergy diagnostics in order to manage allergic patients effectively. This entails accurate identification of the sensitizing allergens, reduction in the need for food challenges, effective risk-assessment and management through patient selection for specific immunotherapy. It may be helpful that laboratories supporting allergy clinics provide these services as part of their testing repertoire. In this study, UK National External Quality Assessment Service (NEQAS) Immunology, Immunochemistry & Allergy (IIA, Sheffield, UK) conducted a survey of participants in order to assess service provision.
Methods
An allergen component testing survey was distributed via UK NEQAS IIA as part of the total IgE scheme (n 5 248) and specific IgE scheme (n 5 383) to the participating UK and other European laboratories offering allergy diagnostic testing to ascertain the breadth of allergy services and local practices including allergen component testing.
The survey contained 25 questions; eight questions focused on the geographical location of the participating laboratory, its workload, requesting pattern and the basic diagnostic allergy services provided, while the remaining 17 focused particularly on the use of allergen component testing.
The responses from this survey were collated in a spreadsheet for analysis.
Results
Overall, 19% (n 5 72) of all participants in the specific IgE scheme surveyed (n 5 383) provided responses. However, not all participants answered every question and therefore the response rate is quoted for each question where appropriate. A full summary of survey questions and the number of responses received (including yes/no breakdown) can be found in Supporting information, Appendix 1.
Location, allergy workload and requesting sources
In terms of the geographical location, more than half (n 5 40, 56%) of the responding laboratories were located in other European Union (EU) countries followed by 26% (n 5 19) in the United Kingdom, and a smaller number (n 5 13, 18%) were non-EU.
In 2013 and 2014, it appears that on average 40% of respondents performed up to 10 000 allergy tests per annum. Roughly 20% of responding laboratories performed between 20 000 and 30 000 tests (Table 1) . Interestingly, a number of laboratories (n 5 15 in 2013 and 21 in 2014) performed the highest number of tests: between 30 000 and 100 0001 tests per annum (Table 1) .
There was a wide variation in the number of allergy test requests coming from both primary and secondary care settings. Of 72 respondents, 32% (n 5 23) stated that up to 20% were from a source other than primary or secondary care (Table 2 ). This may reflect private allergy testing provided in some areas.
Receipt and processing of allergy requests
More than half the respondents (55%, n 5 35 of a total of 64) vetted allergy requests on receipt for appropriateness. The majority of these were other EU (n 5 17) laboratories followed by the United Kingdom (n 5 10).
Interestingly, most services do not require a completed allergy questionnaire to provide clinical information for interpretation and allergen selection: the majority 95% (n 5 62) of total 65 respondents answered 'no', while only 5% (n 5 3) did so (two from UK laboratoriess and one other EU laboratory).
Of 67 respondents, the majority (65%, n 5 44) performed allergy tests on all allergens requested, while 35% (n 5 23) did not. These may be due to processing issues, e.g. insufficient sample received or vetting protocol to ensure relevant testing. However, the participants were not asked to provide further details for not doing so.
In total, 23% (15 of 64 respondents) used both allergen mixtures and panels, while a higher proportion (45%, 29 of 64 respondents) used allergen mixtures only. Phadiatop methodology was used by 9% (n 5 6) of the responding 64 laboratories.
Allergen component testing

Availability
Allergen component testing was offered routinely by 78% (n 5 45) of the 58 respondents. This included 84% (n 5 26) of all other EU, 69% (n 5 11) UK and 73% (n 5 8) non-EU laboratories.
Access to primary care
A significant proportion (74%, n 5 41) of the responding 56 laboratories from all three regions permitted allergen component requests from general practitioners (GPs) and/ or primary care health professionals. This comprised 81% (n 5 25) of all other EU, 70% (n 5 7) non-EU and 60% (n 5 9) UK laboratories.
Gating policy
Interestingly, 35% (n 5 19 of 54 respondents) stated that component testing is performed only if the allergen screen was positive. Nearly 60% of all UK laboratories (n 5 9 of a total of 15) used this approach. In contrast, the response from other EU and non-EU laboratories varied greatly, in that a significant proportion (n 5 21 and n 5 8, respectively) allowed component testing regardless of the allergen screen outcome. The breakdown of yes/no responses to question 11 (Supporting information, Appendix S1) illustrates these striking regional differences. Hence, it appears that the United Kingdom has a different gating policy compared with other regions surveyed.
There was roughly an equal proportion of laboratories stating that component testing was allergen-dependent (yes, 53%, n 5 26) and allergen-independent (no, 47%, n 5 24).
Test selection policy
When asked if there was a testing algorithm for allergy and/or allergen components testing, a significant proportion of the 55 respondents did not have any algorithm for allergy (n 5 34, 63%) or for the components (n 5 38, 67%). However, a group of laboratories stated that they had algorithms for allergy (n 5 21) and component testing (n 5 18), respectively. The majority of these were EU laboratories outside the United Kingdom (Fig. 1) . 
Cut-off levels
The vast majority of the 45 responding laboratories reported the cut-off range for allergen components to be 0Á35 KUA/l (47%, n 5 21) followed by 0Á1 KUA/l (33%, n 5 15), while a small proportion reported other variations of uncertain provenance such as 0Á3 ISU-E, 1Á5 AU/ml, > 0Á35 or even < 0Á01 KUA/l. The survey did not explore if any such alternatives were validated locally according to International Organization for Standardization (ISO) requirements.
Samples
All 47 respondents (100%) stated 'serum' as the preferred matrix, including two EU laboratories that accept both serum and plasma. Of the 42 respondents, 57% (n 5 24) stated the minimum volume for testing to be 0Á3 ml, followed by 0Á5 ml in 33% (n 5 14) and 1Á0 ml in 10% (n 5 4) of the responding laboratories.
Repertoire
The survey explored which of the 17 allergen component tests are offered by the participating laboratories. The results are summarized in Fig. 2 . Approximately two-thirds of the respondents provided either 'yes/no' responses. The majority of laboratories offer components for: (a) peanut (n 5 46), (b) egg (n 5 42) and (c) venoms (n 5 37), followed by nuts (n 5 36) and omega-5-gliadin (n 5 36). On average, more laboratories provide components for all the listed 17 allergens except one (meat alpha-gal), as illustrated in Fig. 2 .
Use of recombinants in peanut allergic patients
Routine diagnosis
Forty-seven laboratories responded to whether they performed allergen component testing routinely for peanut-positive patients. Only 38% (n 5 18) answered 'yes', including 12 EU laboratories, while the remaining 62% (n 5 29) answered 'no'.
Risk stratification
Interestingly, a significant proportion, 74% (n 5 34) of 46 respondents, stated that they 'used' the results for peanut components to stratify clinical risk of patients having a significant reaction. This included 78% (n 5 21) other EU, 73% (n 5 8) UK and 63% (n 5 5) non-EU laboratories.
The participants were asked if they felt there was sufficient understanding regarding allergen component testing among: (a) immunology laboratory staff, (b) hospital specialists and (c) GPs. The results are summarized in Fig. 3 . A key finding was that 78% (n 5 40) of respondents agreed 'yes' for immunology laboratory staff, while 92% (n 5 47) agreed 'no' for GPs. There appeared to be a similar perception of the need for enhanced understanding among hospital specialists, where a somewhat similar 42% (n 5 22) were felt to have sufficient understanding and 58% required educational input.
Guidance
Finally, in order to gauge participants' awareness of any national guidelines relating to allergen component testing, it transpired that the vast majority (80%, n 5 41 of 51 respondents) were not aware of any such guidance material. Those who answered 'yes' (n 5 10) specified various sources, including the British Society for Allergy & Clinical Need for an allergen component external quality assessment (EQA) scheme
Eighty-four per cent (n 5 43 of 51 respondents) of respondents would be interested in participating in a pilot EQA scheme for allergen component testing.
Discussion
This survey provides an overview of the provision of laboratory diagnostic services and use of allergen component testing across the United Kingdom and the rest of Europe. Overall, it confirms that there is a wide variation in laboratory practices even within the same geographical location. The most probable explanation for these observed differences is the lack of standardized approach and disparity in local clinical practices. In terms of laboratory testing, it appears that a minority of laboratories offer more comprehensive testing including the allergen components, whereas others provide only the basic specific IgE screening tests.
The receipt and processing of samples is also highly variable, in that only a small number of laboratories appear to have protocols in place to demand-manage their workload or ensure appropriate test selection, such as vetting of allergy test requests. This demand management appeared to be most common in non-UK laboratories.
Furthermore, a few laboratories (n 5 3) restrict processing of allergy requests to those that have an accompanying completed questionnaire proforma (to ensure that sufficient information is available to ensure appropriate testing and useful interpretation). However, the vast majority perform testing for all allergens requested by the clinician, including mixtures and panels, and therefore are totally dependent upon the clinician's knowledge to ensure appropriate test selection and interpretation. The EAACI position paper on food allergy (2013) [11] , although suggesting the use of CRD in complex cases whereby standard skin prick testing and specific IgE testing was inconclusive, also highlighted the need for further clinical studies to elucidate fully the diagnostic accuracy of CRD. Notably, in a recently published 'Molecular allergology user guide 2016', the task force of EAACI proposed integrating CRD into the traditional top-down and bottom-up diagnostic approaches to create a 'U-shaped' strategy which allows one to reach a 'precise' molecular allergy diagnosis in this modern era of personalized medicine [12] .
NICE guidance (DG24) in the United Kingdom has also been published recently, which recommends that only experienced specialists should utilize multi-parameter component testing chips such as the ISAC, noting that their interpretation is complex and the evidence base currently insufficient to make further recommendations [13] .
Worldwide, a higher proportion of laboratories permit component testing requests from primary care professionals (GPs), who may or may not have the knowledge and expertise to interpret the results accordingly (Fig. 3) . Despite this, the laboratories generally reported that they felt knowledge of allergen component testing was suboptimal in a large proportion of requesters from both primary and secondary care.
A few laboratories restricted availability of allergen component testing to primary care and reserved it exclusively for immunology consultants, allergy specialists and paediatric allergy clinicians. This approach is justified by the need for careful clinical history-taking skills and clinical judgement in selecting and interpreting tests [13] .
The existing repertoire of components for common foods was widely available. Most respondents provided tests for various allergen component categories, including peanut, egg, venom and nuts (Fig. 2) . In addition, some of the non-UK EU laboratories provided component testing for additional allergens such as wheat, fruits, animals, etc. However, fewer laboratories (38%, n 5 17 of 45 respondents) reported the availability of very specific components for rare allergies, e.g. meat alpha-gal component testing for delayed-type anaphylaxis to red meat and chimeric anticancer drug 'cetuximab' [1] .
Harmonization of the diagnostic approach through agreed algorithms appears to be lacking. Although allergen component testing is offered routinely by a significant number of laboratories (78%, n 5 45 of 58 respondents), algorithms for selecting and interpreting allergen components or allergy testing in general are rarely used, and many laboratories perform tests as requested and do not modify or gate the requests. Consequently, the majority of laboratories reported performing these tests regardless of the allergen screen outcome. Interpreting the result of a positive component test where the whole extract screen is negative will be a challenge, and some might argue that it is a waste of resources to perform specific testing on screennegative samples.
Furthermore, there was little awareness of national guidelines relating to component testing among the users (80%, n 5 41 of 51 respondents lacked awareness). A significant proportion of users (74%, n 5 34 of 46 respondents) reported the local 'use' of peanut components to stratify clinical risk of patients in peanut challenge. However, only 38% reported performing routine allergen component testing for peanut-positive patients at the time of first testing. This, in itself, may indicate variability in practice.
Conclusion
This survey highlights the increasing use of CRD, accompanied by an apparent lack of harmonization of approach, and identifies concerns about the need for education of test requesters in primary and secondary care settings. It also demonstrates geographical differences in terms of testing across the United Kingdom and the rest of Europe.
Agreed local or national guidelines may help to harmonize laboratory diagnostics strategies and illustrate the need for external quality assessments of the test performance of CRD, together with enhanced education on their use.
